1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

 
• By Mandy Jackson

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Microscopic image of a gastrointestinal stromal tumor (GIST). Malignant potential depends on size, location and mitotic activity. Targeted therapy with Imatinib (Gleevec) may prevent recurrence. - Image
Deciphera's ripretinib targets GIST cells with KIT and PDGFRa mutations. • Source: Shutterstock

Deciphera Pharmaceuticals Inc.'s ripretinib met and potentially exceeded expectations in the placebo-controlled Phase III INVICTUS clinical trial testing the KIT and PDGFRa kinase switch control inhibitor in fourth-line treatment of gastrointestinal stromal tumors (GIST), justifying the filing of a new drug application (NDA) with the US Food and Drug Administration in the first quarter of 2020.

The company reported median progression-free survival (mPFS) in INVICTUS – the trial's primary endpoint – of 6.3 months (27.6 weeks) for ripretinib-treated patients versus one month (4.1 weeks) in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.